D-Hormone analog alfacalcidol: An update on its role in post-menopausal osteoporosis and rheumatoid arthritis management

Aging Clinical and Experimental Research

Volumn 17, Issue 2, 2005, Pages 133-142

  Richy, Florent ^a,c   Deroisy, Rita ^b   Lecart, Marie Paule ^a,b,c   Hanssens, Linda ^a,c   Mawet, Audrey ^a,c   Reginster, Jean Yves ^a,b,c  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c WHO Collaborating Center for Public Health Aspects of Rheumatic Diseases   (Belgium)

Author keywords

Alfacalcidol; Osteoporosis; Rheumatoid arthritis

Indexed keywords

24,25 DIHYDROXYVITAMIN D; ALFACALCIDOL; ALKALINE PHOSPHATASE; CALCITONIN; CALCITRIOL; CALCIUM; COLECALCIFEROL; CORTICOSTEROID; CYTOCHROME P450 2C11; CYTOCHROME P450 3A4; ERGOCALCIFEROL; HORMONE ANALOG; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; MESSENGER RNA; OKT 4; OKT 8; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE; PLACEBO; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D; 1-HYDROXYCHOLECALCIFEROL; 25 HYDROXYVITAMIN D; 25-HYDROXYVITAMIN D; DRUG DERIVATIVE; HYDROXYCOLECALCIFEROL;

ARTICLE; BIOLOGICAL ACTIVITY; BONE DENSITY; CELLULAR IMMUNITY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CYTOKINE PRODUCTION; DRUG ABSORPTION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG INHIBITION; DRUG METABOLISM; FALLING; FRACTURE; HEMODIALYSIS; HUMAN; HYPERCALCEMIA; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; META ANALYSIS; NONHUMAN; OSTEOLYSIS; PARATHYROID HORMONE BLOOD LEVEL; POSTMENOPAUSE OSTEOPOROSIS; RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW; VITAMIN D DEFICIENCY; AGED; BLOOD; FEMALE; METABOLISM; MIDDLE AGED; REVIEW; SKELETAL MUSCLE;

ANIMALIA;

ACCIDENTAL FALLS; AGED; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; HYDROXYCHOLECALCIFEROLS; IMMUNE SYSTEM; MIDDLE AGED; MUSCLE, SKELETAL; OSTEOPOROSIS, POSTMENOPAUSAL; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 23244446804     PISSN: 15940667     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03324586     Document Type: Article

References (127)

1. Stokstad E. Nutrition. The vitamin D deficit. Science 2003; 302: 1886-8.
2. Takeyama K, Kitanaka S, Sato T, Kobori M, Yanagisawa J, Kato S. 25-Hydroxyvitamin D3 1alpha-hydroxylase and vitamin D synthesis. Science 1997; 277: 1827-30.
3. Fu GK, Portale AA, Miller WL. Complete structure of the human gene for the vitamin D 1 alpha-hydroxylase, P450clalpha. DNA Cell Biol 1997; 16: 1499-507.
4. St-Arnaud R, Arabian A, Travers R, et al. Deficient mineralization of intramembranous bone in vitamin D-24-hydroxylase-ablated mice is due to elevated 1,25-dihydroxyvitamin D and not to the absence of 24,25-dihydroxyvitamin D. Endocrinology 2000; 141: 2658-66.
5. Boyan BD, Sylvia VL, McKinney N, Schwartz Z. Membrane actions of vitamin D metabolites 1alpha,25(OH)2D3 and 24R,25(OH)2D3 are retained in growth plate cartilage cells from vitamin D receptor knockout mice. J Cell Biochem 2003; 90: 1207-23.
6. Tanaka H. Vitamin D metabolites and bone. In: Feldman D, Glorieux FH, Pike JW, eds. Vitamin D. Academic Press, San Diego 1997: 305-12.
7. Seo EG, Norman AW. Three-fold induction of renal 25-hydroxyvitamin D3-24-hydroxylase activity and increased serum 24,25-dihydroxyvitamin D3 levels are correlated with the healing process after chick tibial fracture. J Bone Miner Res 1997; 12: 598-606.
8. Carpenter TO, Keller M, Schwartz D, et al. 24,25 Dihydroxyvitamin D supplementation corrects hyperparathyroidism and im proves skeletal abnormalities in X-linked hypophosphatemic rickets- a clinical research center study. J Clin Endocrinol Metab 1996; 81: 2381-8.
9. Jones G, Ramshaw H, Zhang A, et al. Expression and activity of vitamin D-metabolizing cytochrome P450s (CYP1alpha and CYP24) in human nonsmall cell lung carcinomas. Endocrinology 1999; 140: 3303-10.
10. Yamasaki T, Izumi S, Ide H, Ohyama Y. Identification of a novel rat microsomal vitamin D3 25-hydroxylase. J Biol Chem 2004; 279: 22848-56.
11. Gupta RP, Hollis BW, Patel SB, Patrick KS, Bell NH. CYP3A4 is a Human Microsomal Vitamin D 25-Hydroxylase. J Bone Miner Res 2004; 19: 680-8.
12. Kream BE, Reynolds RD, Knutson JC, Eisman JA, DeLuca HF. Intestinal cytosol binders of 1,25-dihydroxyvitamin D and 25-hydroxyvitamin D. Arch Biochem Biophys 1976; 176: 779-87.
13. DeLuca HF. New concepts of vitamin D functions. Ann NY Acad Sci USA 1992; 669: 59-68.
14. Zittermann A. Vitamin D in preventive medicine: are we ignoring the evidence? Br J Nutr 2003; 89: 552-72.
15. Ooms ME, Lips P, Roos JC, et al. Vitamin D status and sex hormone binding globulin: determinants of bone turnover and bone mineral density in elderly women. J Bone Miner Res 1995; 10: 1177-84.
16. Beckerman P, Silver J. Vitamin D and the parathyroid. Am J Med Sci 1999; 317: 363-9.
17. Lau KH, Baylink DJ. Vitamin D therapy of osteoporosis: plain vitamin D therapy versus active vitamin D analog (D-hormone) therapy. Calcif Tissue Int 1999; 65: 295-306.
18. Christakos S, Raval-Pandya M, Wernyj RP, Yang W. Genomic mechanisms involved in the pleiotropic actions of 1,25-dihydroxyvitamin D3. Biochem J 1996; 316 (Pt 2): 361-71.
19. Kinyamu HK, Gallagher JC, Prahl JM, DeLuca HF, Petranick KM, Lanspa SJ. Association between intestinal vitamin D receptor, calcium absorption, and serum 1,25 dihydroxyvitamin D in normal young and elderly women. J Bone Miner Res 1997; 12: 922-8.
20. Hosseinpour F, Wikvall K. Porcine microsomal vitamin D(3) 25-hydroxylase (CYP2D25). Catalytic properties, tissue distribution, and comparison with human CYP2D6. J Biol Chem 2000; 275: 34650-5.
21. Hosseinpour F, Ibranovic I, Tang W, Wikvall K. 25-Hydroxylation of vitamin D3 in primary cultures of pig hepatocytes: evidence for a role of both CYP2D25 and CYP27A1. Biochem Biophys Res Commun 2003; 303: 877-83.
22. Ueno Y, Shinki T, Nagai Y, Murayama H, Fujii K, Suda T. In vivo administration of 1,25-dihydroxyvitamin D3 suppresses the expression of RANKL mRNA in bone of thyroparathyroidectomized rats constantly infused with PTH. J Cell Biochem 2003; 90: 267-77.
23. Kwan Tat S, Padrines M, Theoleyre S, Heymann D, Fortun Y. IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. Cytokine Growth Factor Rev 2004; 15: 49-60.
24. Alvarez-Hernandez D, Naves M, Santamaria I, Menarguez J, Torregrosa V, Cannata J. Response of parathyroid glands to calcitriol in culture: is this response mediated by the genetic polymorphisms in vitamin D receptor? Kidney Int Suppl 2003; 85: S19-22.
25. Slatopolsky E, Brown AJ. Vitamin D and its analogs in chronic renal failure. Osteoporos Int 1997; 7 (Suppl 3): S202-8.
26. Ledger GA, Burritt MF, Kao PC, O'Fallon WM, Riggs BL, Khosla S. Abnormalities of parathyroid hormone secretion in elderly women that are reversible by short term therapy with 1,25-dihydroxyvitamin D3. J Clin Endocrinol Metab 1994; 79: 211-6.
27. Parfitt AM. The hyperparathyroidism of chronic renal failure: a dis-order of growth. Kidney Int 1997; 52: 3-9.
28. Gallacher SJ, Cowan RA, Fraser WD, Logue FC, Jenkins A, Boyle IT. Acute effects of intravenous 1 alpha-hydroxychole-calciferol on parathyroid hormone, osteocalcin and calcitriol in man. Eur J Endocrinol 1994; 130: 141-5.
29. Shiraishi A, Higashi S, Okawa H. The effect of 1-a(OH)D3 on bone metabolism in parathyroidectomized rats with continuous PTH perfusion. Osteoporos Int 1997; 7: 35.
30. Suda T, Takahashi N, Martin TJ. Modulation of osteoclast differentiation. Endocr Rev 1992; 13: 66-80.
31. Lind L, Wengle B, Lithell H, Ljunghall S. Reduction in serum alkaline phosphatase levels by treatment with active vitamin D (alphacalcidol) in primary and secondary hyperparathyroidism and in euparathyroid individuals. Scand J Urol Nephrol 1991; 25: 233-6.
32. Somjen D, Weisman Y, Kaye AM. Pretreatment with 1,25(OH)2 vitamin D or 24,25(OH)2 vitamin D increases synergistically responsiveness to sex steroids in skeletal-derived cells. J Steroid Biochem Mol Biol 1995; 55: 211-7.
33. Long J, Liu P, Zhang Y, et al. Interaction effects between estrogen receptor alpha gene, vitamin D receptor gene, age, and sex on bone mineral density in Chinese. J Hum Genet 2003; 48: 514-9.
34. van Leeuwen JP, van den Bemd GJ, van Driel M, Buurman CJ, Pols HA. 24,25-Dihydroxyvitamin D(3) and bone metabolism. Steroids 2001; 66: 375-80.
35. Chen JT, Shiraki M, Hasumi K, et al. 1-alpha-Hydroxyvitamin D3 treatment decreases bone turnover and modulates calcium-regulating hormones in early postmenopausal women. Bone 1997; 20: 557-62.
36. Hofbauer LC, Dunstan CR, Spelsberg TC, Riggs BL, Khosla S. Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines. Biochem Biophys Res Commun 1998; 250: 776-81.
37. Cantorna MT, Woodward WD, Hayes CE, DeLuca HF. 1,25-dihydroxyvitamin D3 is a positive regulator for the two anti-encephalitogenic cytokines TGF-beta 1 and IL-4. J Immunol 1998; 160: 5314-9.
38. Zofkova I, Kancheva RL. The effect of 1,25(OH)2 vitamin D3 on CD4+/CD8+ subsets of T lymphocytes in postmenopausal women. Life Sci 1997; 61: 147-52.
39. Richy F, Ethgen O, Bruyere O, Reginster JY. Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. Osteoporos Int 2004; 15: 301-10.
40. Richy F, Schacht E, Bruyere O, Ethgen O, Gourlay M, Reginster JY. Vitamin D analogs versus plain vitamin D in preventing bone loss and osteoporosis-related fractures: a comparative meta-analysis. Calcif Tissue Int 2005 (in press).
41. Hayashi Y, Fujita T. Decrease of vertebral fracture in osteoporotics by administration of 1-alpha-hydroxy-vitamin D3. JBMM 1992; 10: 184-8.
42. Menczel J, Foldes J, Steinberg R, et al. Alfacalcidol (alpha D3) and calcium in osteoporosis. Clin Orthop 1994; 300: 241-7.
43. Orimo H, Shiraki M, Hayashi Y, et al. Effects of 1 alpha-hydroxyvitamin D3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis. Calcif Tissue Int 1994; 54: 370-6.
44. Shiraki M, Kushida K, Yamazaki K, Nagai T, Ioue T, Orimo H. Ef-fects of 2 years' treatment of osteoporosis with la-hydroxy vitamin D3 on bone mineral density and incidence of fracture: a placebocontrolled, double-blind prospective study. Endocr J 1996; 43: 211-20.
45. Reginster JY, Kuntz D, Verdickt W, et al. Prophylactic use of alfacalcidol in corticosteroid-induced osteoporosis. Osteoporos Int 1999; 9: 75-81.
46. Sato Y, Manabe S, Kuno H, Oizumi K. Amelioration of osteopenia and hypovitaminosis D by 1a-hydroxyvitamin D3 in elderly patients with Parkinson's disease. J Neurosurg Psychiatry 1999; 66: 64-8.
47. Sato Y, Maruoka H, Oizumi K. Amelioration of hemiplegia-associated osteopenia more than 4 years after stroke by 1-a-hydroxyvitamin D3 and calcium supplementation. Stroke 1997; 28: 736-9.
48. Lakatos P, Nagy Z, Kiss L, Horvath C, Takacs I, Foldes J. Prevention of corticosteroid-induced osteoporosis by alphacalcidol. Z Rheumatol 2000; 59: 48-52.
49. Aloia JF. Role of calcitriol in the treatment of postmenopausal osteoporosis. Metabolism 1990; 39 (4 Suppl 1): 35-8.
50. Ebeling PR, Wark JD, Yeung S, et al. Effects of calcitriol or calcium on bone mineral density, bone turnover, and fractures in men with primary osteoporosis: a two-year randomized, double blind, double placebo study. J Clin Endocrinol Metab 2001; 86: 4098-103.
51. Sambrook P, Henderson NK, Keogh A, et al. Effect of calcitriol on bone loss after cardiac or lung transplantation. J Bone Miner Res 2000; 15: 1818-24.
52. Gallagher JC, Riggs BL, Recker RR, Goldgar D. The effect of calcitriol on patients with postmenopausal osteoporosis with special reference to fracture frequency. Proc Soc Exp Biol Med 1989; 191: 287-92.
53. Gallagher JC, Goldgar D. Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol. A randomized controlled study. Ann Intern Med 1990; 113: 649-55.
54. Gallagher JC, Fowler SE, Detter JR, Sherman SS. Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss. J Clin Endocrinol Metab 2001; 86: 3618-28.
55. Lambrinoudaki I, Chan DT, Lau CS, Wong RW, Yeung SS, Kung AW. Effect of calcitriol on bone mineral density in pre-menopausal Chinese women taking chronic steroid therapy. A randomized, double blind, placebo controlled study. J Rheumatol 2000; 27: 1759-65.
56. Sambrook P. Alfacalcidol and calcitriol in the prevention of bone loss after organ transplantation. Calcif Tissue Int 1999; 65: 341-3.
57. Hedstrom M. Hip fracture patients, a group of frail elderly people with low bone mineral density, muscle mass and IGF-I levels. Acta Physiol Scand 1999; 167: 347-50.
58. Ritz E, Boland R, Kreusser W. Effects of vitamin D and parathyroid hormone on muscle: potential role in uremie myopathy. Am J Clin Nutr 1980; 33: 1522-9.
59. Pleasure D, Wyszynski B, Sumner A, et al. Skeletal muscle calcium metabolism and contractile force in vitamin D-deficient chicks. J Clin Invest 1979; 64: 1157-67.
60. Curry OB, Basten JF, Francis MJ, Smith R. Calcium uptake by sarcoplasmic reticulum of muscle from vitamin D-deficient rabbits. Nature 1974; 249: 83-4.
61. Curry O, Francis MJ, Smith R. Proceedings: The effects of vitamin D deficiency on the isolated sarcoplasmic reticulum of muscle. Clin Sci Mol Med 1974; 46: 7P.
62. Stroder J. Hypothyroidism and rachitis. Arch Kinderheilkd [Archives of Pediatrics] 1965; 173: 105-9.
63. Bischoff HA, Borchers M, Gudat F, et al. In situ detection of 1,25-dihydroxyvitamin D3 receptor in human skeletal muscle tissue. Histochem J 2001; 33: 19-24.
64. Bischoff HA, Stahelin HB, Tyndall A, Theiler R. Relationship between muscle strength and vitamin D metabolites: are there therapeutic possibilities in the elderly? Z Rheumatol 2000; 59 (Suppl 1): 39-41.
65. Bischoff HA, Stahelin HB, Urscheler N, et al. Muscle strength in the elderly: its relation to vitamin D metabolites. Arch Phys Med Rehabil 1999; 80: 54-8.
66. Rimaniol JM, Authier FJ, Chariot P. Muscle weakness in intensive care patients: initial manifestation of vitamin D deficiency. Intensive Care Med 1994; 20: 591-2.
67. Buitrago C, Vazquez G, De Boland AR, Boland R. The vitamin D receptor mediates rapid changes in muscle protein tyrosine phosphorylation induced by 1,25(OH)(2)D(3). Biochem Biophys Res Commun 2001; 289: 1150-6.
68. Visser M, Deeg DJ, Lips P. Low vitamin D and high parathyroid hormone levels as determinants of loss of muscle strength and muscle mass (sarcopenia): the Longitudinal Aging Study Amsterdam. J Clin Endocrinol Metab 2003; 88: 5766-72.
69. Zittermann A, Schleithoff SS, Tenderich G, Berthold HK, Korfer R, Stehle P. Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure? J Am Coll Cardiol 2003; 41: 105-12.
70. Ziambaras K, Dagogo-Jack S. Reversible muscle weakness in patients with vitamin D deficiency. West J Med 1997; 167: 435-9.
71. Grady D, Halloran B, Cummings S, et al. 1,25-Dihydroxyvitamin D3 and muscle strength in the elderly: a randomized controlled trial. J Clin Endocrinol Metab 1991; 73: 1111-7.
72. Lips P, Graafmans WC, Ooms ME, Bezemer PD, Bouter LM. Vitamin D supplementation and fracture incidence in elderly persons. A randomized, placebo-controlled clinical trial. Ann Intern Med 1996; 124: 400-6.
73. Glerup H, Mikkelsen K, Poulsen L, et al. Hypovitaminosis D myopathy without biochemical signs of osteomalacic bone involvement. Calcif Tissue Int 2000; 66: 419-24.
74. Pfeifer M, Begerow B, Minne HW, Abrams C, Nachtigall D, Hansen C. Effects of a short-term vitamin D and calcium supplementation on body sway and secondary hyperparathyroidism in elderly women. J Bone Miner Res 2000; 15: 1113-8.
75. Bischoff H, Stahelin H, Dick W, et al. Effects of vitamin D and calcium supplementation on falls: a randomized controlled trial. J Bone Miner Res 2003; 18: 343-51.
76. Dukas L, Bischoff HA, Lindpaintner LS, et al. Alfacalcidol reduces the number of fallers in a community-dwelling elderly population with a minimum calcium intake of more than 500 mg daily. J Am Geriatr Soc 2004; 52: 230-6.
77. Janssen HC, Samson MM, Verhaar HJ. Vitamin D deficiency, muscle function, and falls in elderly people. Am J Clin Nutr 2002; 75: 611-5.
78. O'Kelly J, Hisatake J, Hisatake Y, Bishop J, Norman A, Koeffler HP. Normal myelopoiesis but abnormal T lymphocyte responses in vitamin D receptor knockout mice. J Clin Invest 2002; 109: 1091-9.
79. Towers TL, Freedman LP. Granulocyte-macrophage colony-stimulating factor gene transcription is directly repressed by the vitamin D3 receptor. Implications for allosteric influences on nuclear receptor structure and function by a DNA element. J Biol Chem 1998; 273: 10338-48.
80. DeLuca HF, Cantorna MT. Vitamin D: Its role and uses in immunology. FASEB J 2001; 15: 2579-85.
81. Lemire JM. Immunomodulatory actions of 1,25-dihydroxyvitamin D3. J Steroid Biochem Mol Biol 1995; 53: 599-602.
82. Lemire JM, Archer DC, Beck L, Spiegelberg HL. Immunosuppressive actions of 1,25-dihydroxyvitamin D3: preferential inhibition of Th1 functions. J Nutr 1995; 125 (Suppl 6): 1704S-8S.
83. Garcion E, Sindji L, Nataf S, Brachet P, Darcy F, Montero-Menei CN. Treatment of experimental autoimmune encephalomyelitis in rat by 1,25-dihydroxyvitamin D3 leads to early effects within the central nervous system. Acta Neuropathol (Berl) 2003; 105: 438-48.
84. Oelzner P, Muller A, Deschner F, et al. Relationship between disease activity and serum levels of vitamin D metabolites and PTH in rheumatoid arthritis. Calcif Tissue Int 1998; 62: 193-8.
85. Vaisberg MW, Kaneno R, Franco MF, Mendes NF. Influence of cholecalciferol (vitamin D3) on the course of experimental systemic lupus erythematosus in F1 (NZBxW) mice. J Clin Lab Anal 2000; 14: 91-6.
86. Zella JB, DeLuca HF. Vitamin D and autoimmune diabetes. J Cell Biochem 2003; 88: 216-22.
87. Froicu M, Weaver V, Wynn TA, McDowell MA, Welsh JE, Cantorna MT. A crucial role for the vitamin D receptor in experimental inflammatory bowel diseases. Mol Endocrinol 2003; 17: 2386-92.
88. Demoor-Fossard M, Galera P, Santra M, Iozzo RV, Pujol JP, Redini F. A composite element binding the vitamin D receptor and the retinoic X receptor alpha mediates the transforming growth factor-beta inhibition of decorin gene expression in articular chondrocytes. J Biol Chem 2001; 276: 36983-92.
89. Tanaka H, Abe E, Miyaura C, et al. 1 alpha,25-Dihydroxycholecalciferol and a human myeloid leukaemia cell line (HL-60). Biochem J 1982; 204: 713-9.
90. Wiese RJ, Uhland-Smith A, Ross TK, Prahl JM, DeLuca HF. Up-regulation of the vitamin D receptor in response to 1,25-dihydroxyvitamin D3 results from ligand-induced stabilization. J Biol Chem 1992; 267: 20082-6.
91. Yamauchi Y, Tsunematsu T, Konda S, Hoshino T, Itokawa Y, Hoshizaki H. A double blind trial of alfacalcidol on patients with rheumatoid arthritis (RA). Ryumachi [official journal of the Japan Rheumatism Association] 1989; 29: 11-24.
92. Yang S, Smith C, Prahl JM, Luo X, DeLuca HF. Vitamin D deficiency suppresses cell-mediated immunity in vivo. Arch Biochem Biophys 1993; 303: 98-106.
93. Yang S, Smith C, DeLuca HF. 1 alpha, 25-Dihydroxyvitamin D3 and 19-nor-1 alpha, 25-dihydroxyvitamin D2 suppress immunoglobulin production and thymic lymphocyte proliferation in vivo. Biochem Biophys Acta 1993; 1158: 279-86.
94. Kameda H, Takeuchi T. Osteoporosis associated with rheumatoid arthritis. Nippon Rinsho [Japonese Journal of Clinical Medicine] 2003; 61: 292-8.
95. Haugeberg G, Orstavik RE, Kvien TK. Effects of rheumatoid arthritis on bone. Curr Opin Rheumatol 2003; 15: 469-75.
96. Brosch S, Redlich K, Pietschmann P. |Pathogenesis of osteoporosis in rheumatoid arthritis]. Acta Med Austriaca 2003; 30: 1-5.
97. Hirayama T, Danks L, Sabokbar A, Athanasou NA. Osteoclast formation and activity in the pathogenesis of osteoporosis in rheumatoid arthritis. Rheumatology (Oxf) 2002; 41: 1232-9.
98. Sugiyama T. Involvement of interleukin-6 and prostaglandin E2 in periarticular osteoporosis of postmenopausal women with rheumatoid arthritis. J Bone Miner Metab 2001; 19: 89-96.
99. Joe B, Griffiths MM, Remmers EF, Wilder RL. Animal models of rheumatoid arthritis and related inflammation. Curr Rheumatol Rep 1999; 1: 139-48.
100. Yilmaz M, Kendirli SG, Altintas D, Bingol G, Antmen B. Cytokine levels in serum of patients with juvenile rheumatoid arthritis. Clin Rheumatol 2001; 20: 30-5.
101. Pascher E, Perniok A, Becker A, Feldkamp J. Effect of 1alpha,25(OH)2-vitamin D3 on TNF alpha-mediated apoptosis of human primary osteoblast-like cells in vitro. Horm Metab Res 1999;31:653-6.
102. Bottcher J, Malich A, Pfeil A, et al. Potential clinical relevance of digital radiogrammetry for quantification of periarticular bone demineralization in patients suffering from rheumatoid arthritis depending on severity and compared with DXA. Eur Radiol 2004; 14: 631-7.
103. Goertz B, Fassbender WJ, Williams JC, et al. Vitamin D receptor genotypes are not associated with rheumatoid arthritis or biochemical parameters of bone turnover in German RA patients. Clin Exp Rheumatol 2003; 21: 333-9.
104. Lee CK, Hong JS, Cho YS, Yoo B, Kim GS, Moon HB. Lack of relationship between vitamin D receptor polymorphism and bone erosion in rheumatoid arthritis. J Korean Med Sci 2001; 16: 188-92.
105. Gough A, Sambrook P, Devlin J, et al. Effect of vitamin D receptor gene alleles on bone loss in early rheumatoid arthritis. J Rheumatol 1998; 25: 864-8.
106. Lisker R, Lopez MA, Jasqui S, et al. Association of vitamin D receptor polymorphisms with osteoporosis in Mexican postmenopausal women. Hum Biol 2003; 75: 399-403.
107. Ravid A, Koren R, Maron L, Liberman UA. 1,25(OH)2D3 increases cytotoxicity and exocytosis in lymphokine-activated killer cells. Mol Cell Endocrinol 1993; 96: 133-9.
108. Rau R. Use of glucocorticoids in rheumatoid arthritis. Inhibition of disease progression versus risk of steroid osteoporosis. Z Rheumatol [German Journal of Rheumatology] 2001; 60: 485-91.
109. Solomon DH, Katz JN, Jacobs JP, La Tourette AM, Coblyn J. Management of glucocorticoid-induced osteoporosis in patients with rheumatoid arthritis: rates and predictors of care in an academic rheumatology practice. Arthritis Rheum 2002; 46: 3136-42.
110. Reginster JY, de Froidmont C, Lecart MP, Sarlet N, Defraigne JO. Alphacalcidol in prevention of glucocorticoid-induced osteoporosis. Calcif Tissue Int 1999; 65: 328-31.
111. Yudoh K, Matsuno H, Osada R, Nakazawa F, Katayama R, Kimura T. Decreased cellular activity and replicative capacity of osteoblastic cells isolated from the periarticular bone of rheumatoid arthritis patients compared with osteoarthritis patients. Arthritis Rheum 2000; 43: 2178-88.
112. Ohlsson C, Bengtsson BA, Isaksson OG, Andreassen TT, Slootweg MC. Growth hormone and bone. Endocr Rev 1998; 19: 55-79.
113. Ohlsson C, Vidal O. Effects of growth hormone and insulin-like growth factors on human osteoblasts. Eur J Clin Invest 1998; 28: 184-6.
114. Toyoda T, Inokuchi S, Saito S, Horie Y, Tomita S. Bone loss of the radius in rheumatoid arthritis. Comparison between 34 patients and 40 controls. Acta Orthop Scand 1996; 67: 269-73.
115. Lee S, Szlachetka M, Christakos S. Effect of glucocorticoids and 1,25-dihydroxyvitamin D3 on the developmental expression of the rat intestinal vitamin D receptor gene. Endocrinology 1991; 129: 396-401.
116. Godschalk M, Levy JR, Downs RW, Jr. Glucocorticoids decrease vitamin D receptor number and gene expression in human osteosarcoma cells. J Bone Miner Res 1992; 7: 21-7.
117. Blotta MH, DeKruyff RH, Umetsu DT. Corticosteroids inhibit IL-12 production in human monocytes and enhance their capacity to induce IL-4 synthesis in CD4+ lymphocytes. J Immunol 1997; 158: 5589-95.
118. Schacht E. Osteoporosis in rheumatoid arthritis- significance of alfacalcidol in prevention and therapy. Z Rheumatol [German Journal of Rheumatology] 2000; 59 (Suppl 1): 10-20.
119. McKnight AJ, Zimmer GJ, Fogelman I, Wolf SF, Abbas AK. Effects of IL-12 on helper T cell-dependent immune responses in vivo. J Immunol 1994; 152: 2172-9.
120. Boonstra A, Barrat FJ, Crain C, Heath VL, Savelkoul HF, O'Garra A. 1alpha,25-Dihydroxyvitamin D3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells. J Immunol 2001; 167: 4974-80.
121. Andjelkovic Z, Vojinovic J, Pejnovic N, et al. Disease modifying and immunomodulatory effects of high dose 1 alpha (OH) D3 in rheumatoid arthritis patients. Clin Exp Rheumatol 1999; 17: 453-6.
122. Brohult J, Jonson B. Effects of large doses of calciferol on patients with rheumatoid arthritis. A double-blind clinical trial. Scand J Rheumatol 1973; 2: 173-6.
123. Dottori L, D'Ottavio D, Brundisini B. Calcifediol and calcitonin in the therapy of rheumatoid arthritis. A short-term controlled study. Minerva Med 1982; 73: 3033-40.
124. Yamauchi Y, Tsunematsu T, Honda S, Hoshino T, Itokawa Y. A double blind trial of alfacalcidol on patients with rheumatoid arthritis (RA). Ryumachi [Official Journal of the Japan Rheumatism Association] 1989; 29: 11-24.
125. Hein G, Oelzner P. Vitamin D metabolites in rheumatoid arthritis: findings-hypotheses-consequences. Z Rheumatol [German Journal of Rheumatology] 2000; 59 (Suppl 1): 28-32.
126. Buckley LM, Leib ES, Cartularo KS, Vacek PM, Cooper SM. Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996; 125: 961-8.
127. Gukasian DA, Nasonov EL, Balabanova RM, Smirnov AV, Vlasova IS. Effects of alfacalcidol on mineral density of bone tissue in patients with rheumatoid arthritis. Klin Med [Clinical Medicine] 2001; 79: 47-50.